Show simple item record

dc.contributor.authorDahlberg, Seth T.
dc.contributor.authorWeinstein, Howard
dc.contributor.authorHendel, Robert C.
dc.contributor.authorMcSherry, Brenda A.
dc.contributor.authorLeppo, Jeffrey A.
dc.date2022-08-11T08:09:32.000
dc.date.accessioned2022-08-23T16:34:31Z
dc.date.available2022-08-23T16:34:31Z
dc.date.issued1992-10-01
dc.date.submitted2009-03-10
dc.identifier.citationJ Nucl Med. 1992 Oct;33(10):1783-8.
dc.identifier.issn0161-5505 (Print)
dc.identifier.pmid1403145
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38351
dc.description.abstractMyocardial perfusion agents labeled with 99mTc offer improved physical imaging properties compared to 201TI. Teboroxime is a new 99mTc-labeled compound for myocardial perfusion imaging that shows a high myocardial extraction and rapid clearance. Sixty-seven patients underwent planar teboroxime imaging with a rapid acquisition protocol. Agreement of teboroxime and 201TI for the presence or absence of disease occurred in 56/65 patients (86%). There was agreement (normal or abnormal) between the two agents in 156/195 vessels (80%) and 457/585 segments (78%). When abnormal segments (ischemia or infarction) were compared, teboroxime showed significantly more ischemic segments (89/135, 66%) than did 201TI (73/135, 54%, p < 0.05). Teboroxime offers accuracy comparable to 201TI for the diagnosis of coronary artery disease and may improve the detection of ischemic or viable myocardium. In addition, its rapid myocardial clearance permits stress/rest imaging in 60-90 min.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=1403145&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://jnm.snmjournals.org/content/33/10/1783.long
dc.subjectCoronary Angiography
dc.subjectCoronary Disease
dc.subjectEvaluation Studies as Topic
dc.subjectExercise Test
dc.subjectFemale
dc.subjectHeart
dc.subjectHumans
dc.subjectImage Processing, Computer-Assisted
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectOrganotechnetium Compounds
dc.subjectOximes
dc.subjectSensitivity and Specificity
dc.subjectThallium Radioisotopes
dc.subjectTime Factors
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titlePlanar myocardial perfusion imaging with technetium-99m-teboroxime: comparison by vascular territory with thallium-201 and coronary angiography
dc.typeArticle
dc.source.journaltitleJournal of nuclear medicine : official publication, Society of Nuclear Medicine
dc.source.volume33
dc.source.issue10
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1216
dc.identifier.contextkey770194
html.description.abstract<p>Myocardial perfusion agents labeled with 99mTc offer improved physical imaging properties compared to 201TI. Teboroxime is a new 99mTc-labeled compound for myocardial perfusion imaging that shows a high myocardial extraction and rapid clearance. Sixty-seven patients underwent planar teboroxime imaging with a rapid acquisition protocol. Agreement of teboroxime and 201TI for the presence or absence of disease occurred in 56/65 patients (86%). There was agreement (normal or abnormal) between the two agents in 156/195 vessels (80%) and 457/585 segments (78%). When abnormal segments (ischemia or infarction) were compared, teboroxime showed significantly more ischemic segments (89/135, 66%) than did 201TI (73/135, 54%, p < 0.05). Teboroxime offers accuracy comparable to 201TI for the diagnosis of coronary artery disease and may improve the detection of ischemic or viable myocardium. In addition, its rapid myocardial clearance permits stress/rest imaging in 60-90 min.</p>
dc.identifier.submissionpathoapubs/1216
dc.contributor.departmentDepartment of Radiology, Division of Nuclear Medicine
dc.source.pages1783-8


This item appears in the following Collection(s)

Show simple item record